This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Dec 2011

Lilly & ImmunoGen Form Antibody-drug Conjugate Collaboration

Lilly will use ImmunoGen's maytansinoid Targeted Antibody Payload technology with Lilly monoclonal antibodies to develop novel ADC anticancer therapeutics.

Eli Lilly and Co. and ImmunoGen have established an antibody-drug conjugate (ADC) collaboration.

 

Lilly will pay an upfront fee of $20 million for rights to take a limited number of exclusive licenses to use ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology with Lilly monoclonal antibodies to develop novel ADC anticancer therapeutics.

 

Each license taken entitles ImmunoGen to receive milestone payments potentially totaling approximately $200 million, in addition to royalties on the sales of any resulting products. ImmunoGen also is entitled to receive financial compensation for any research and/or manufacturing done on behalf of Lilly. Lilly is responsible for the development, manufacturing, and marketing of any products resu

Related News